Skip To Main Content
Hiroji Iwata on Muck Rack

Hiroji Iwata

As seen in: Nature, Medscape, The Lancet, Cancer Discovery, Future Medicine, ONCOLOGY journal, OncLive, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hiroji

Contact Hiroji, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events

|
By Hope Rugo, David W. Cescon, Peter Schmid, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo Verified, Hiroji Iwata, Oleg Lipatov, Felipe Garcia Cruz, Felipe Santa Cruz, Carlos Henrique Barrios, Roberto Hegg, Sherene Loi, Maria Gion, Péter Árkosy, Lili Yao, Jaime Mejia Verified, Wilbur Pan, Javier Cortés, Marco Torregroza Otero, Rafal Tarnawski
| Nature Verified
Abstract Pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in the phase 3 randomized KEYNOTE-355 study in participants with previously untreated, advanced triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) ≥ 10.
Open in Who Shared Issue with article?

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer

|
By François-Clément Bidard, Carlos H. Barrios, Giampaolo Bianchini, Adam Brufsky, Stephen Chia, Javier Cortés, Massimo Cristofanilli, Giuseppe Curigliano, Shaheenah Dawood, Lorenzo Gerratana, Antonio Giordano, Michail Ignatiadis, Hiroji Iwata, Wolfgang Janni, Elgene Lim, Kevin Kalinsky, Cynthia X. MA, Erica L. Mayer, Arielle Medford, Jason A. Mouabbi, Joyce O’Shaughnessy, Yeon Hee Park, Javier G. Pascual, Pedram Razavi, Sarah L. Sammons, Jose Sandoval, Luisana Sisca, Paolo Tarantino, Seth A. Wander, Gustavo Werutsky, Nicholas Turner
| Nature Verified
Introduction In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned.
Open in Who Shared Issue with article?

44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)

|
By Ian Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Hiroji Iwata, Tatsuya Toyama, Yutaka Yamamoto, Damien Hansra, Masato Takahashi, Kumiko Koyama, Tatsuya Inoue, Yoshimi Tanaka, David Sternberg, Kan Yonemori, Akihiko Osaki, Takatoshi Yonekura, Joseph Mostillo, Shoichi Ohwada
| ONCOLOGY journal Verified
Background Human epidermal growth factor receptor 3 (HER3) is overexpressed in many types of cancer, including 30%-50% of breast cancers (BCs): Overexpression of HER3 in BC is associated with poor prognosis. No HER3-directed therapies have been approved for the treatment of any cancer.
Open in Who Shared Issue with article?
See all 13 licensed articles (14 Total)